The increase in binding affinity of complex molecules due to optimization of hydrophobic interactions at the target-drug interface, comparatively demonstrate better efficacy of drug leads.
Where as, how hydrogen bonds optimize the hydrophobic interactions, at the protein-ligand interface that increases the binding affinity of complex molecules, has not been properly analyzed.
Moreover, most data on the binding affinity of complexes were not available.
Results evaluated the binding affinity of complexes 1 3 to CT-DNA by UV and presented binding constants (Kb) of 4.522 × 102 M−1, 3.859 × 102 M−1 and 4.025 × 102 M−1, respectively.
The experimental results suggest that three complexes bind to CT-DNA through an intercalative mode and the DNA-binding affinity of complex 1 is greater than that of complexes 2 and 3.
Experimental results indicated that Ln III) complexes and ligand could bind to CT DNA via the intercalation mode and that the binding affinities of Ln III) complexes are higher than that of free ligand.
And the calculations predict a number of single substitutions on RBD, receptor or antibody that could remarkably elevate the binding affinities of those complexes.
The regulatory roles of histone modifications include the mediation of binding affinities of protein complexes, such as those related to transcriptional and splicing machinery (Kolasinska-Zwierz et al. 2009; Luco et al. 2010, 2011; Negre et al. 2011).
Like DNA methylation, hPTMs have been found to mediate the binding affinities of protein complexes, such as those related to transcriptional and splicing machinery (Kolasinska-Zwierz et al. 2009; Luco et al. 2010, 2011; Negre et al. 2011), as well as to control the local accessibility of chromatin (Henikoff 2008; Venkatesh et al. 2012; Zentner and Henikoff 2013).
These different levels of enrichment could be due to different binding affinities of the RGL2-complex to these promoters; it could also indicate different binding partners of RGL2 in the complex that binds to DNA.
